360 related articles for article (PubMed ID: 17363489)
1. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Thomas HD; Calabrese CR; Batey MA; Canan S; Hostomsky Z; Kyle S; Maegley KA; Newell DR; Skalitzky D; Wang LZ; Webber SE; Curtin NJ
Mol Cancer Ther; 2007 Mar; 6(3):945-56. PubMed ID: 17363489
[TBL] [Abstract][Full Text] [Related]
2. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Calabrese CR; Almassy R; Barton S; Batey MA; Calvert AH; Canan-Koch S; Durkacz BW; Hostomsky Z; Kumpf RA; Kyle S; Li J; Maegley K; Newell DR; Notarianni E; Stratford IJ; Skalitzky D; Thomas HD; Wang LZ; Webber SE; Williams KJ; Curtin NJ
J Natl Cancer Inst; 2004 Jan; 96(1):56-67. PubMed ID: 14709739
[TBL] [Abstract][Full Text] [Related]
3. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
4. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Curtin NJ; Wang LZ; Yiakouvaki A; Kyle S; Arris CA; Canan-Koch S; Webber SE; Durkacz BW; Calvert HA; Hostomsky Z; Newell DR
Clin Cancer Res; 2004 Feb; 10(3):881-9. PubMed ID: 14871963
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA; Rozanska AL; Thomas HD; Mulligan EA; Drew Y; Castelbuono DJ; Hostomsky Z; Plummer ER; Boddy AV; Tweddle DA; Curtin NJ; Clifford SC
Clin Cancer Res; 2009 Feb; 15(4):1241-9. PubMed ID: 19174487
[TBL] [Abstract][Full Text] [Related]
6. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
Skalitzky DJ; Marakovits JT; Maegley KA; Ekker A; Yu XH; Hostomsky Z; Webber SE; Eastman BW; Almassy R; Li J; Curtin NJ; Newell DR; Calvert AH; Griffin RJ; Golding BT
J Med Chem; 2003 Jan; 46(2):210-3. PubMed ID: 12519059
[TBL] [Abstract][Full Text] [Related]
7. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
8. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
[TBL] [Abstract][Full Text] [Related]
9. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
Ali M; Telfer BA; McCrudden C; O'Rourke M; Thomas HD; Kamjoo M; Kyle S; Robson T; Shaw C; Hirst DG; Curtin NJ; Williams KJ
Clin Cancer Res; 2009 Oct; 15(19):6106-12. PubMed ID: 19789326
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
11. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
Canan Koch SS; Thoresen LH; Tikhe JG; Maegley KA; Almassy RJ; Li J; Yu XH; Zook SE; Kumpf RA; Zhang C; Boritzki TJ; Mansour RN; Zhang KE; Ekker A; Calabrese CR; Curtin NJ; Kyle S; Thomas HD; Wang LZ; Calvert AH; Golding BT; Griffin RJ; Newell DR; Webber SE; Hostomsky Z
J Med Chem; 2002 Nov; 45(23):4961-74. PubMed ID: 12408707
[TBL] [Abstract][Full Text] [Related]
12. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
13. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
[TBL] [Abstract][Full Text] [Related]
14. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
[TBL] [Abstract][Full Text] [Related]
15. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
16. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Tentori L; Portarena I; Barbarino M; Balduzzi A; Levati L; Vergati M; Biroccio A; Gold B; Lombardi ML; Graziani G
Mol Pharmacol; 2003 Jan; 63(1):192-202. PubMed ID: 12488552
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Russo AL; Kwon HC; Burgan WE; Carter D; Beam K; Weizheng X; Zhang J; Slusher BS; Chakravarti A; Tofilon PJ; Camphausen K
Clin Cancer Res; 2009 Jan; 15(2):607-12. PubMed ID: 19147766
[TBL] [Abstract][Full Text] [Related]
20. Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Griffin RJ; Srinivasan S; Bowman K; Calvert AH; Curtin NJ; Newell DR; Pemberton LC; Golding BT
J Med Chem; 1998 Dec; 41(26):5247-56. PubMed ID: 9857092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
